Eurofins Genomics, an international market leader in genomic services, has been accredited according to ISO17025:2005 standards since 2007 demonstrating an outstanding track record in high quality molecular testing. ISO 17025 is an important international analytical standard used by testing and calibration laboratories. Over the course of the past seven years, the accreditation has been successively expanded to include many more analytical applications.
Eurofins Genomics provides analytical solutions under the ISO17025 quality standard for applications in veterinary medicine, pharmaceutical testing, food, feed and commodity testing as well as in health care. The latter includes medical laboratory testing in the context of clinical studies and genetic diagnostics.
Eurofins Genomics ISO17025 accreditation covers mass spectrometry based DNA analysis and molecular testing methods, for example Sanger sequencing, quantitative Real-Time PCR and fragment length polymorphisms analysis.
In April 2014, next generation sequencing (NGS) technologies based on Illumina and Roche 454 platforms were added to extend the Eurofins Genomics ISO17025 accredited service portfolio. "The addition of our next generation sequencing services to our ISO17025 accreditation was the next logical step in response to our growing customer base in the regulated market and in areas with specific quality assurance needs." says Peter Persigehl, General Manager Eurofins Genomics Europe.
"With the extension of our ISO17025 accredited service portfolio to NGS, Eurofins Genomics is even more capable to provide of providing tailored solutions for customers rapidly growing and new fields of applications" says Bruno Poddevin, Senior Vice-President Eurofins Genomics.
Illumina is a trademark of Illumina / 454 is a trademark of Roche.
Weiterführende Informationen finden sich hier:
http://www.eurofinsgenomics.eu/...
http://www.eurofinsgenomics.eu/...
Eurofins Genomics provides analytical solutions under the ISO17025 quality standard for applications in veterinary medicine, pharmaceutical testing, food, feed and commodity testing as well as in health care. The latter includes medical laboratory testing in the context of clinical studies and genetic diagnostics.
Eurofins Genomics ISO17025 accreditation covers mass spectrometry based DNA analysis and molecular testing methods, for example Sanger sequencing, quantitative Real-Time PCR and fragment length polymorphisms analysis.
In April 2014, next generation sequencing (NGS) technologies based on Illumina and Roche 454 platforms were added to extend the Eurofins Genomics ISO17025 accredited service portfolio. "The addition of our next generation sequencing services to our ISO17025 accreditation was the next logical step in response to our growing customer base in the regulated market and in areas with specific quality assurance needs." says Peter Persigehl, General Manager Eurofins Genomics Europe.
"With the extension of our ISO17025 accredited service portfolio to NGS, Eurofins Genomics is even more capable to provide of providing tailored solutions for customers rapidly growing and new fields of applications" says Bruno Poddevin, Senior Vice-President Eurofins Genomics.
Illumina is a trademark of Illumina / 454 is a trademark of Roche.
Weiterführende Informationen finden sich hier:
http://www.eurofinsgenomics.eu/...
http://www.eurofinsgenomics.eu/...
